Evidence map›Paper›PMID 24648182›Full record

ArticleEuropean journal of immunology2014

Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function.

Melanie Stumpf, Xuyu Zhou, Shunsuke Chikuma, Jeffrey A Bluestone

Open access · greenAbstract read
In one paragraph

Article in European journal of immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  4. Article
  5. Review
  6. Glutamate Receptor Interacting Protein 1 Regulates CD4(+) CTLA-4 Expression and Transplant Rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016
    Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Melanie StumpfDiabetes Center and the Department of Medicine, University of California, San Francisco, CA, USA; Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.
Xuyu Zhou
Shunsuke Chikuma
Jeffrey A Bluestone
University of California, San Francisco · USChinese Academy of Sciences · CNUniversity of Colorado Denver · US

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRUMMEL, MATTHEW F · 2003 to 2019
$21.8M
Src tyrosine kinases and autoimmunity.P01AI035297 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BLUESTONE, JEFFREY A · 1993 to 2010
$16.5M
UCSF Autoimmunity Center of ExcellenceU19AI056388 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ABBAS, ABUL K. · 2003 to 2013
$6.3M
CTLA 4 ANTAGONISM DURING T CELL ACTIVATIONF33AI009895 · NIAID · UNIVERSITY OF CHICAGO · PI BLUESTONE, JEFFREY A · 1997 to 1997
–
NCI NIH HHS P30 CA014599NIAID NIH HHS F33 AI009895NIAID NIH HHS P01 AI035297NIAID NIH HHS P01 AI35297NIAID NIH HHS U19 AI056388NIDDK NIH HHS P30 DK063720NIDDK NIH HHS P30DK63720-06A1
6 · The paper itself

Abstract

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a major negative regulatory molecule for T-cell activation with a complex biology and function. CTLA-4 is known to regulate homeostatic lymphoproliferation as well as tolerance induction and has been proposed to be an important effector molecule by which Treg cells suppress immunity. The immunoregulatory properties of CTLA-4 are primarily mediated by competition with the costimulator CD28 for ligand binding but also by delivering negative signals to T cells through its cytoplasmic tail. In this study, we addressed the effect of directly mutating the amino acid residue, Tyrosine 201 (Tyr201), of the intracellular domain of CTLA-4 in situ and its implications in T-cell function in the context of autoimmunity. Therefore, a novel CTLA-4 knock-in mouse (Y201V KI) was generated, in which Tyr201 was replaced by a valine that could not be phosphorylated. Mice expressing the CTLA-4 mutant molecule were generally healthy and did not show signs of disruption of T-cell homeostasis under steady-state conditions seen in CTLA-4 deficient mice. However, T cells isolated from Y201V KI mice expressed higher levels of CTLA-4 on the cell surface and displayed a Th2-biased phenotype following TCR stimulation. Furthermore, Y201V KI mice developed exacerbated disease as compared to wild-type upon antigen-specific T-cell activation in an in vivo model of EAE. Importantly, the Y201V mutation resulted in impaired suppressive activity of Treg cells while T effector function remained intact. These data suggest that effects associated with and mediated through Tyr201 of CTLA-4s intracellular domain are critical for Treg-cell function.

Indexed as

Immune ToleranceAmino Acid SubstitutionAnimalsCTLA-4 AntigenEncephalomyelitis, Autoimmune, ExperimentalMiceMice, Inbred BALB CMice, TransgenicMutation, MissenseProtein Structure, TertiaryT-Lymphocytes, RegulatoryTyrosineCTLA-4 AntigenTyrosineAutoimmunityCTLA-4EAE/MSTreg cells

Identifiers

PMID24648182
PMCPMC4051436
OpenAlexW1988576454

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.